In 2009, B7H6 was discovered as a tumor-specific ligand for NKp30.8 In fact, B7H6 has been found to be upregulated in several tumor types, establishing the NKp30/B7H6 as an attractive axis to be exploited for immunotherapy,9–13,31,32 including the development of targeting approaches against B7H6.31,33. This evidence concerns the gene NCR3 and neoplasm.